ClinicalTrials.gg
CompletedNCT07529613T-DXd_HER2LowUpdated Apr 14, 2026

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase 1/2 interventional study of T-DXd and Nivolumab in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by National Cancer Center Hospital East. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by National Cancer Center Hospital East · Phase 1/2, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Dec 2023, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms — 8 open to participants now, 11 under way, 3 of them phase 3. trastuzumab deruxtecan · Stomach Neoplasms.

Enrollment
11th of 14
30 · median 78
Started
2023
the only one that year
Phase 1/2
3 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
National Cancer Center Hospital East

Among the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, this one is the 11th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 1/2, and was the 14th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of the combination therapy of T-DXd, nivolumab, and chemotherapy in patients with untreated HER2-low gastric or gastroesophageal junction adenocarcinoma, and to determine the recommended dose. Subsequently, the efficacy and safety at the recommended dose will be assessed.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • Trastuzumab Deruxtecan
  • T-DXd
  • DS-8201a
  • Gastric Cancer
  • HER2-Low
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Historical confirmation of adenocarcinoma of the gastric, gastroesophageal junction, or esophagus is considered by the investigator or subinvestigator to be unresectable advanced or recurrent.
  2. low expression: IHC1+, or IHC2+ and ISH negative [FISH or DISH method] in HER2 test of the primary lesion or lesion.
  3. Having one or more as specified in Guideline version 1.1.
  4. Systemic treatment is untreated (local radiation and surgical treatment is acceptable).
  5. Age at the date of is 20 years or older.
  6. Performance status (PS) of 0 or 1.
  7. Has >= 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrollment.
  8. Has a interval (QTc) =\< 470 ms in females, or QTc =\< 450 ms in males based on a 12-lead screening within 28 days before enrollment (allowed on the same day of the week). [Fridericia's correction is recommended]
  9. The most recent laboratory value within 14 days before enrollment meets all of the following. (Examinations on the same day of the week 2 weeks prior to the date of enrollment are allowed.) (1) =\< 1,500/mm3 (2) =\< 9.0 g/dL (3) count =\< 100,000/mm3 (4)Total =\< 1.5 mg/dL (5)(GOT) =\< 100 IU/L =\< 200 IU/L in the presence of hepatic involvement (6)ALT(GPT) =\< 100 IU/L =\< 200 IU/L in the presence of hepatic involvement (7)Creatinine =\< 1.5 mg/dL (8)PT() \< 1.8 and aPTT \< 60 seconds
  10. Has adequate treatment before enrollment (allowed on the same day of the week), defined as:

    i. Surgery with general anesthesia: >= 4 weeks ii. Radiotherapy: >= 4 weeks (including palliative stereotactic body radiation therapy to the chest; palliative stereotactic body radiation therapy to other than the chest >= 2 weeks; abdominal vertebral bodies should be included in the abdomen).

    iii. Chloroquine and hydroxychloroquine: >= 15 days

  11. No blood transfusion was performed within 7 days before registration. (Transfusions on the same day of the week prior to the day of enrollment are allowed.)
  12. Female of have a negative pregnancy test within 7 days before enrollment (allowed on the same day of the week). Male and Female of childbearing potential agree to for a period (4 months for male and 7 months for Female) from informed consent to the last dose of study drug.
  13. Written informed consent of participation in the study has been obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  1. Has a prior chemotherapy for unresectable advanced or recurrent gastric/esophagogastric junction/esophageal adenocarcinoma. (Note: Patients are eligible if they have received prior preoperative or postoperative therapy. However, treatment must have been completed at least 6 months prior to enrollment and progression must have occurred at least 6 months after completion of treatment).
  2. to the central nervous system have been identified. (Only if CNS involvement is clinically suspected, cerebral CT scanning or MRI confirmation is mandatory at the time of screening.).
  3. Has a medical history of myocardial infarction or congestive heart failure ( Classes II-IV) within 6 months before enrollment, corresponding to the **troponin levels diagnosed as myocardial infarction as defined by the *manufacturer within 28 days before enrollment (allowed on the same day), unstable angina, or any serious arrhythmia requiring treatment.

    *: Manufacturer refers to a testing company used by a study implementation institution.

    **: Enrollment is allowed if a subject exceeds , if the subject is examined and myocardial infarction can be excluded.

  4. Active cancer that requires aggressive treatment, such as chemotherapy or operation
  5. Has serious (hospitalized) complications (intestinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes mellitus that is difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, psychiatric disorders, cerebrovascular disorders, etc.)
  6. Grade 1 or residual adverse effects of prior therapy that have not resolved to baseline (excluding hair loss).

    Note:Participants with Grade2 chronic toxicity (Defined as no worse than Grade 2 for at least 3 months prior to enrollment and manageable with standard therapy) who are considered by the investigator to have treatment-related toxicity are eligible for enrollment.

    • Chemotherapy-Induced Neuropathy
    • Malaise
  7. Has history of gastrointestinal perforation and/or gastrointestinal fistula within 6 months before enrollment.
  8. Has any of the following infections:

    • HBs antigen positive
    • HBs antibody or HBc antibody and positive
    • Active (e.g., if HCV RNA is detected qualitatively) Patients who are HBsAg positive but who have achieved HBV DNA level \< 1.3 log IU/mL (2.1 log copies/mL) after treatment with antiviral drugs such as NAs, are eligible for the study.
  9. infection has been documented.
  10. Lung diseases are defined as:

    • Has a history of non-infectious interstitial lung disease or pneumonitis that required treatment, has interstitial lung disease or pneumonitis, or these lung diseases cannot be ruled out by radiographic examination before enrollment.
    • Severe pulmonary impairment (e.g., pulmonary embolism within 3 months prior to enrollment, serious bronchial asthma, severe , restrictive pulmonary disease, or pleural effusion).
    • Lung-related or connective tissue or inflammatory diseases (e.g., rheumatoid arthritis, Sjogren's syndrome, or sarcoidosis) with clinically severe pulmonary risks.
    • Has history of pneumonectomy.
  11. Has history of concomitant autoimmune disease or chronic or recurrent autoimmune disease.
  12. Administration of systemic adrenocortical hormones (except prophylactic administration for tests or allergic reactions, and temporary use for the purpose of reducing edema associated with radiotherapy) or is required, or has received these treatments within 14 days before enrollment in the study.
  13. Has unhealed wounds, ulcers, or fractures.
  14. If you have uncontrolled acute systemic infection that requires Infusion intravenous antibiotic, antiviral, or antifungal drug.
  15. If you have received a (mRNA vaccine or replication-defective adenovirus vaccine is not regarded as live attenuated vaccine) within 30 days before the initial administration.
  16. If patients are a pregnancy or breastfeeding patient.
  17. Patients who do not take appropriate measures during the study and contraceptive period
  18. Severe to the active ingredient or additive of the study drug has been confirmed.
  19. Has history/complications of severe hypersensitivity reactions to other monoclonal antibodies.
  20. Unwilling or unable to comply with any of implementation matters stipulated in the study implementation protocol or any of the instructions of the physician.
  21. The investigator or sub investigator considered it ineligible for the study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    T-DXd plus Nivolumab, Capecitabine

    Drug: T-DXd · Drug: Nivolumab · Drug: Capecitabine · Drug: Oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs in Phase Ib part

    The incidence of DLTs in each cohort will be calculated for the DLT evaluable population.

    Time frame: 3 weeks

  2. ORR in Phase II part

    The ORR is defined as the proportion of participants whose best overall response, as assessed by the principal investigator or sub-investigator according to the RECIST guidelines version 1.1, is either CR or PR.

    Time frame: 1 year

Secondary outcomes

  1. Duration of Response (DoR)

    The duration is defined as the period from the date on which a complete response (CR) or partial response (PR) was first confirmed based on the overall response according to the RECIST Guidelines version 1.1, up to the earlier of the date on which disease progression (PD based on imaging) was determined or the date of death from any cause.

    Time frame: 1 year

  2. Disease Control Rate (DCR)

    The DCR is defined as the proportion of participants whose best overall response according to the RECIST guidelines version 1.1 was CR or PR, or whose SD persisted for 6 weeks or longer.

    Time frame: 1 year

  3. Progression-Free Survival (PFS)

    The period is calculated from the date of registration until the earlier of the date of confirmed progression or the date of death from any cause.

    Time frame: 1 year

  4. Overall Survival (OS)

    The period is calculated from the date of registration until the date of death from any cause.

    Time frame: 1 year

  5. Incidence of adverse events

    The treatment-emergent AEs will be summarized by CTCAE v5.0

    Time frame: 1 year

Other outcomes

  1. HER2 expression at central review

    Analysis of efficacy in cases confirmed to have low HER2 expression at central review (ORR, PFS, DoR, DCR, OS)

    Time frame: 1 year

  2. Evaluation of tumor tissue biomarkers by immunohistochemistry/in situ hybridization and RNA sequencing in the PhIb and PhII cohorts

    This outcome measure relates to an ancillary biomarker research study conducted as part of the main trial. Exploratory assessment of tumor tissue biomarkers will be performed using archived FFPE tumor specimens, including PD-L1, CD8, CD4, EBER-ISH, MMR protein expression, CLDN18.2, EGFR, FGFR, and MET expression by immunohistochemistry and/or in situ hybridization, and gene expression profiling by RNA sequencing.

    Time frame: 1 year

07

Study locations

1 site
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Dec 2025, 24 months.

Of 67 non-industry phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 133. This study's 24 months is below that.

Counting every sponsor, half of 158 studies reached it within 60 months; a quarter within 40 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 14, 2026
StartActual
Dec 20, 2023
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07529613
Lead sponsor
National Cancer Center Hospital East
Responsible party
Kohei Shitara (Chief of Gastroenterology and Gastrointestinal Oncology Division, National Cancer Center Hospital East) — Principal investigator
First posted
Apr 14, 2026
Start date
Dec 20, 2023
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Apr 14, 2026

Study contacts

Kohei Shitara, MD
principal investigator · National Cancer Center Hospital East

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Nivolumab · Capecitabine · Oxaliplatin

Start the discussion